KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Asset Writedowns and Impairment (2018 - 2023)

Jazz Pharmaceuticals (JAZZ) has 6 years of Asset Writedowns and Impairment data on record, last reported at $61.0 million in Q4 2023.

  • For Q4 2023, Asset Writedowns and Impairment changed N/A year-over-year to $61.0 million; the TTM value through Dec 2023 reached $194.7 million, changed N/A, while the annual FY2023 figure was $61.0 million, 54.35% down from the prior year.
  • Asset Writedowns and Impairment reached $61.0 million in Q4 2023 per JAZZ's latest filing, down from $133.6 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $136.1 million in Q1 2020 and bottomed at $61.0 million in Q4 2023.
  • Average Asset Writedowns and Impairment over 3 years is $110.3 million, with a median of $133.6 million recorded in 2022.